About us

Fresenius Kabi Austria GmbH

Our ultimate goal is to meet the needs and expectations of our customers. The quality of our products and services is synonymous with improving the quality of life of our patients.

Fresenius Kabi Austria GmbH

Fresenius Kabi in Austria specializes in products for infusion and nutrition therapy. We develop, produce and distribute a full portfolio of IV drugs and nutrition products, and with these product groups we are one of the leading companies in the Austrian hospital and homecare sectors.

Riesner

General Manager Heinz Riesner

Jens Sauter

General Manager Jens Sauter

 

Our plants in Graz and Linz manufacture products for both the Austrian market and for export markets around the world, with an export rate of approximately 80%. Besides sterile pharmaceuticals, we are also one of the world's largest manufacturers of the carbohydrate pharmaceutical ingredients hydroxyethyl starch (HES) and lactulose.

As a reliable contracting partner we offer our comprehensive development and manufacturing competences to third parties.

Fresenius Kabi Austria, with approximately 1500 employees, is a subsidiary of Fresenius Kabi AG.

Fresenius Kabi AG, in turn, is a division of the international health care company Fresenius SE & Co KGaA.

Company policy Fresenius Kabi Austria

 

Fresenius Kabi worldwide

Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products.

In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched.

Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.

About us

Fresenius Kabi employs more than 40,000 people worldwide.

With our corporate philosophy of "caring for life", we are committed​ to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

In 2019, the company reported sales of more than  € 6.9 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

Key Figures

€ in millions 2019 2018  
Sales

6,919

6,544  

EBITDA1

1,502

1,434

 

EBIT1

1,200 1,139  

Net Income1,2

802  742  
Employees (Dec 31)

39,627

37,843

 


On a comparable basis: before special items and adjusted for IFRS 16 effect

Net income attributable to shareholders of Fresenius SE & Co. KGaA